CA2391416A1 - Oncolytic combinations for the treatment of cancer - Google Patents

Oncolytic combinations for the treatment of cancer Download PDF

Info

Publication number
CA2391416A1
CA2391416A1 CA002391416A CA2391416A CA2391416A1 CA 2391416 A1 CA2391416 A1 CA 2391416A1 CA 002391416 A CA002391416 A CA 002391416A CA 2391416 A CA2391416 A CA 2391416A CA 2391416 A1 CA2391416 A1 CA 2391416A1
Authority
CA
Canada
Prior art keywords
ethyl
propoxy
fluorophenyl
hydroxyphenoxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002391416A
Other languages
English (en)
French (fr)
Inventor
Jerome Herbert Fleisch
William Thomas Mcmillen
Beverly Ann Teicher
Jason Scott Sawyer
Douglas Wade Beight
Edward C. R. Smith
Roger Stuart Benjamin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2391416A1 publication Critical patent/CA2391416A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CA002391416A 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer Abandoned CA2391416A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16478699P 1999-11-11 1999-11-11
US60/164,786 1999-11-11
PCT/US2000/031039 WO2001034137A2 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA2391416A1 true CA2391416A1 (en) 2001-05-17

Family

ID=22596085

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002391416A Abandoned CA2391416A1 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer

Country Status (22)

Country Link
EP (1) EP1231938A2 (es)
JP (1) JP2003513916A (es)
KR (1) KR20020069512A (es)
CN (1) CN1390139A (es)
AR (1) AR032432A1 (es)
AU (1) AU778829B2 (es)
BR (1) BR0015490A (es)
CA (1) CA2391416A1 (es)
CZ (1) CZ20021551A3 (es)
EA (1) EA200200545A1 (es)
HK (1) HK1050132A1 (es)
HU (1) HUP0204449A3 (es)
IL (1) IL148579A0 (es)
MX (1) MXPA02004733A (es)
NO (1) NO20022245L (es)
NZ (1) NZ517667A (es)
PE (1) PE20010701A1 (es)
PL (1) PL355172A1 (es)
SK (1) SK6492002A3 (es)
TR (1) TR200201245T2 (es)
WO (1) WO2001034137A2 (es)
ZA (1) ZA200202822B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034198A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034197A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
CA2408622A1 (en) * 2000-05-09 2001-11-15 Creighton University Methods for inhibiting proliferation and inducing apoptosis in cancer cells
JP2004505047A (ja) 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
CN1302782C (zh) * 2005-01-17 2007-03-07 北京京卫燕康药物研究所有限公司 盐酸吉西他滨溶液型注射剂
ATE529404T1 (de) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc Phenoxyessigsäuren als ppar-delta-aktivatoren
EP1979311B1 (en) 2005-12-22 2012-06-13 High Point Pharmaceuticals, LLC Phenoxy acetic acids as ppar delta activators
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
AU2007307597A1 (en) 2006-10-12 2008-04-17 Institute Of Medicinal Molecular Design. Inc. Carboxylic acid derivatives
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
EP2914587A1 (de) 2012-10-31 2015-09-09 Bayer CropScience AG Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
CN103319466B (zh) * 2013-07-04 2016-03-16 郑州大学 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation

Also Published As

Publication number Publication date
CN1390139A (zh) 2003-01-08
PL355172A1 (en) 2004-04-05
BR0015490A (pt) 2002-07-09
CZ20021551A3 (cs) 2003-02-12
NO20022245L (no) 2002-07-09
NO20022245D0 (no) 2002-05-10
SK6492002A3 (en) 2003-09-11
ZA200202822B (en) 2003-09-23
HUP0204449A2 (hu) 2003-04-28
PE20010701A1 (es) 2001-07-07
TR200201245T2 (tr) 2004-08-23
AU1599001A (en) 2001-06-06
KR20020069512A (ko) 2002-09-04
AR032432A1 (es) 2003-11-12
WO2001034137A2 (en) 2001-05-17
EP1231938A2 (en) 2002-08-21
WO2001034137A3 (en) 2002-02-14
HUP0204449A3 (en) 2006-02-28
IL148579A0 (en) 2002-09-12
MXPA02004733A (es) 2002-08-30
JP2003513916A (ja) 2003-04-15
AU778829B2 (en) 2004-12-23
HK1050132A1 (zh) 2003-06-13
NZ517667A (en) 2004-05-28
EA200200545A1 (ru) 2002-12-26

Similar Documents

Publication Publication Date Title
CA2391416A1 (en) Oncolytic combinations for the treatment of cancer
US9321746B2 (en) Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
CN101503399B (zh) C-芳基葡萄糖苷sglt2抑制剂
TW446704B (en) Naphtho[2,3-B]heteroar-4-yl derivatives for treating metabolic disorders related to insulin resistance or hyperglycemia
ES2397664T3 (es) Derivados de glucopiranósilo que contienen tienilo como antidiabéticos
JP2003531194A (ja) プロスタグランジンｅ阻害薬としてフェニルおよびビアリール誘導体を用いる治療方法および該方法に有用な化合物
EA024083B1 (ru) Новые соединения, связывающие фарнезоидный х-рецептор (fxr) (nr1h4) и модулирующие его активность
US8338481B2 (en) Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer
Giles et al. Synthesis pharmacological evaluation and docking studies of pyrimidine derivatives
CA2390789A1 (en) Oncolytic combinations for the treatment of cancer
TW201831191A (zh) 一種新的硼酸衍生物及其藥物組合物
AU2014364732A1 (en) Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2C adrenoreceptor antagonists
JP2003509419A (ja) カルボン酸類およびアシルスルホンアミド類、そのような化合物を含む組成物、ならびに治療方法
JP2008503567A (ja) α−アリールメトキシアクリレート誘導体を含有する代謝性骨疾患の予防及び治療用医薬組成物
WO2005079803A1 (en) Compounds for treatment of cardiovascular diseases
US20110319458A1 (en) Compound with agitation effect on peroxisome proliferator-activated receptor. process for its preparation and use thereof
WO2001034198A2 (en) Oncolytic combinations for the treatment of cancer
JP6223336B2 (ja) 新規なエストロゲン受容体リガンド
WO2001034197A2 (en) Oncolytic combinations for the treatment of cancer
ES2207108T3 (es) Derivados de acido aril carboxilico y tetrazol con un grupo de carbamoiloxi.
JP2023175716A (ja) リン酸塩誘導体およびその用途
WO2019031470A1 (ja) 新規アミド系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤
CN116848095A (zh) 氘代化合物
KR101360579B1 (ko) 신규 페닐초산 유도체
JP2023511679A (ja) 二置換アダマンチル誘導体、その薬学的に許容される塩、およびこれを有効成分として含む癌の増殖抑制用薬学的組成物

Legal Events

Date Code Title Description
FZDE Discontinued